Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07326709 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
A Phase 3 study of Huntington Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 770
- Enrollment target
- 2
- Study locations
NCT07326709: Recruiting Phase 3 study of Huntington Disease, sponsored by Novartis Pharmaceuticals.
NCT07326709 is a Phase 3 study of Huntington Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 770 participants, above the 613-participant average among 35 other Huntington Disease trials with a reported enrollment target (26% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07326709, a Phase 3 study of Huntington Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 770 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
Primary Outcome
The Composite Unified Huntingtons Disease Ratings Scale (cUHDRS) is an improved composite measure to assess multi-domain clinical progression in HD. The cUHDRS is a combined weighted score of measures of motor function (TMS), cognition (SDMT and SWRT) and overall functional capacity (TFC): cUHDRS = \[(TFC-10.4)/1.9 - (TMS-29.7)/14.9 + (SDMT-28.4)/11.3 + (SWRT - 66.1)/20.1\] + 10. In conjunction with one another, these measures provide a comprehensive, sensitive and specific tool for monitoring
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Votoplam (blinded)
Study Locations (2)
District of Columbia
- Georgetown University - Washington D.C.
Quebec
- Novartis Investigative Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 770 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 3 |
What NCT07326709 shows while recruiting
NCT07326709 is an interventional study that assigns participants to a tested intervention. The registered 770 participants enrollment target is mid-sized for trials with a published cap, above the 613-participant average among 35 other Huntington Disease trials with a reported enrollment target (26% higher).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07326709 reports a single indexed study location in District of Columbia, Quebec.
Frequently Asked Questions
What is clinical trial NCT07326709 about?
NCT07326709 is a clinical study titled "A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease". The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is ...
What is the current status of trial NCT07326709?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 770 participants. The study started on 2026-06-01. Estimated completion is 2030-04-30.
What conditions does trial NCT07326709 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT07326709?
The interventions under investigation include: Placebo (DRUG), Votoplam (blinded) (DRUG).
Who is sponsoring clinical trial NCT07326709?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07326709 being conducted?
This trial has 2 study locations across District of Columbia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07326709's enrollment target sits among peer trials
770 7th of 35 higher than 29 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
COMPLETED · Phase 3
-
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
COMPLETED · Phase 3
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05977348 · 770 participants · NA
Increasing Food Literacy in Preschoolers to Reduce Obesity Risk
- NCT06376994 · 770 participants · Phase 3
Multi-Center Clean Air Randomized Controlled Trial in COPD
- NCT06824467 · 770 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- NCT06907173 · 770 participants · Phase 3
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI